.After increasing $170 million back in February, metabolic disease-focused BioAge Labs has submitted to debut on the general public market.The Eli Lilly-partnered biotech wish to detail on the Nasdaq under the sign “BIOA,” according to documents filed with the Stocks and Swap Percentage. The business has not publicly shared an expected financial volume for the offering.The clinical-stage business promotes lead candidate azelaprag, an orally provided little particle slated to go into stage 2 testing in combo along with semaglutide– marketed by Novo Nordisk under brand Wegovy for weight loss– in the initial one-half of upcoming year. Semaglutide is also sold as Ozempic and also Rybelsus by Novo for diabetes.
Apelin receptor agonist azelaprag is actually created to integrate effectively along with GLP-1 medications, boosting weight-loss while preserving muscle mass. The investigational drug was actually located to be well-tolerated amongst 265 individuals throughout eight phase 1 tests, according to BioAge.Earlier, BioAge got the assistance of Lilly to manage a trial mixing azelaprag along with the Big Pharma’s GLP-1/ GIP receptor agonist tirzepatide, which is marketed for diabetes as Mounjaro and also Zepbound for fat loss. The partners are presently performing a stage 2 trial of azelaprag and also tirzepatide, with topline outcomes assumed in the third quarter of 2025.The biotech is actually also planning a blood insulin level of sensitivity proof-of-concept trial evaluating azelaprag as a monotherapy in the very first one-half of upcoming year to sustain prospective indicator growth.
Additionally, the company considers to inquire the FDA for approval in the second fifty percent of 2025 to release individual screening for an NLRP3 inhibitor targeting metabolic conditions and also neuroinflammation.BioAge’s expected transfer to everyone market follows a light uptick in prepared biotech IPOs from Bicara Therapeutics as well as Zenas Biopharma. Zooming out, the current IPO landscape is a “blended image,” with high quality business still debuting on the general public markets, simply in decreased amounts, depending on to PitchBook.